Steven R. Ruby

Steven R. Ruby is a patent litigation attorney with a focused practice in pharmaceutical and biologics patent disputes, particularly those arising under the Biologics Price Competition and Innovation Act (BPCIA). His client representations consistently involve patentees, as evidenced by his appearances on behalf of Regeneron Pharmaceuticals, Inc. in all tracked cases, indicating a clear plaintiff-side preference in patent enforcement actions.

Mr. Ruby is currently an attorney at Carey Douglas Kessler & Ruby, PLLC, based in Charleston, West Virginia. He has also appeared on behalf of Rothwell, Figg, Ernst & Manbeck in a patent litigation matter. His notable patent litigation experience includes serving as local counsel for Regeneron Pharmaceuticals, Inc. in significant cases such as Regeneron Pharmaceuticals, Inc. v. Samsung Bioepis Co., Ltd., Regeneron Pharmaceuticals, Inc. v. Celltrion, Inc., and Regeneron Pharmaceuticals, Inc. v. Sandoz Inc. These cases are part of broader litigation concerning Regeneron's Eylea® product, where courts have sustained patent validity and infringement against biosimilar manufacturers, leading to preliminary and permanent injunctions.

While Mr. Ruby's professional background includes extensive experience as a former federal prosecutor and chief of white-collar prosecutions, which involved nationally recognized trials and securing the first-ever conviction of a major-company CEO for a workplace safety crime, there is no public record indicating his direct involvement in Patent Trial and Appeal Board (PTAB) or Inter Partes Review (IPR) proceedings. He earned his Juris Doctor from Washington & Lee University School of Law in 2006, graduating first in his class, and a Bachelor of Arts cum laude from Duke University in 2000. He is admitted to practice in West Virginia, New York, and the District of Columbia.